Evidence map›Paper›PMID 28454327›Full record

ArticleOncology letters2017

Stereotactic radiotherapy in the treatment of local recurrences of esophageal cancer.

Marcel Matzenauer, David Vrána, Zuzana Vlachová, Rene Aujesky, Radek Vrba, Cestmir Neoral, Bohuslav Melichar

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Stereotactic body radiotherapy for distant metastases to the head and neck.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
  2. Article
  3. Review
  4. From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer.International journal of molecular sciences · 2018
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Marcel MatzenauerDepartment of Oncology, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic.
David VránaDepartment of Oncology, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic.
Zuzana VlachováDepartment of Oncology, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic.
Rene AujeskyDepartment of Surgery, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic.
Radek VrbaDepartment of Surgery, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic.
Cestmir NeoralDepartment of Surgery, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic.
Bohuslav MelicharDepartment of Oncology, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic.
Palacký University Olomouc · CZNational Institute of Public Health · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Esophageal cancer (EC) consists of tumors with a generally poor prognosis, and treatment options for patients with disease recurrence are extremely limited. Due to this poor patient prognosis, the possible treatment toxicity should be carefully balanced against its potential benefit and patient quality of life. Stereotactic body radiotherapy (SBRT) is a rapidly expanding novel technique combining a short treatment time together with high local efficacy and an acceptable toxicity profile. There are no publications thus far presenting data regarding the usage of SBRT utilizing a conventional linear accelerator in locally recurrent EC patients. In the present study, 2 patients with recurrent EC in the neck lymph nodes were treated by SBRT in the Department of Oncology, University Hospital Olomouc, Czech Republic. The treatment dose was 30 and 40 Gy in 5 daily fractions, with a prescribed dose to 65 and 81% isodose, for each patient respectively, utilizing a volumetric arc therapy technique, a 6-MV photon beam and an Elekta Synergy linear accelerator. The treatment was delivered without any unintentional treatment interruptions and without any treatment-related acute toxicity. The maximum dose in the patients was 45.9 and 49.2 Gy, respectively. The maximum doses for the surrounding major blood vessels were 35.4 and 45.7 Gy, respectively. Maximum doses to the trachea and the esophagus in the first patient were 32.6 and 27.0 Gy. In the second patient, these doses were not clinically significant. SBRT utilizing linear accelerators should be considered in patients with localized recurrent EC, offering the patients the chance for local control with minimal treatment toxicity.

Indexed as

chemotherapyesophageal cancerrecurrencestereotactic radiotherapy

Identifiers

PMID28454327
PMCPMC5403422
OpenAlexW2577550965

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.